Clinical Outcomes and Prognostic Factors in Epithelial-Myoepithelial Carcinoma (EMC) of the Breast
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2025.01.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Utsav Joshi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Moffitt Cancer Center, Tampa, FL. Electronic address: Utsav.joshi@moffitt.org. Hauptthemen laut MEDLINE: Breast Neoplasms, Myoepithelioma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Most published data on EMC consists of individual case reports, and survival outcomes are not clearly defined to guide evidence-based management. METHODS: All women with a histologic diagnosis of EMC irrespective of age and stage at diagnosis till 2018 in the National Cancer Database were included (N = 111). Overall survival (OS) was compared among groups using the Kaplan-Meier and log-rank methods. RESULTS: The median age at diagnosis was 67 years, and 101 (88.6%) were over 50 years of age. Ten percent were ER+/Her2-, 29.7% were ER-/Her2-, 0.9% were Her2+, 5.4% were ER+/Her2 unknown, 24% were ER-/Her2 unknown, and 29.7% had no data on ER status. Most patients underwent surgical resection (91.9%), whereas chemotherapy and radiation were utilized in 35.2% and 40.6% of the patients, respectively. At a median follow-up of 67.6 months, the 5-year OS was 74.3%. Among patients who received chemotherapy or radiation, the 5-year OS was 80.1% (vs. 68.9% in nonrecipients, P = .02) and 83.1% (vs. 68.5% in nonrecipients, P = .03), respectively. The 5-year OS was 82.7%, 76.5%, and 50% for tumor ≤ 2 cm, 2 to 5 cm, and > 5 cm respectively (P = .009). Chemotherapy or radiation treatment were associated with improved OS in tumors >5 cm (both P 5cm) although small sample size and lack of recurrence data limit this conclusion. Studies using larger cohorts are needed to demonstrate objective efficacy of systemic treatment in lymph node positive and metastatic EMC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Moffitt Cancer Center, Tampa, FL. Electronic address: Utsav.joshi@moffitt.org.
- Department of Oncology, Moffitt Cancer Center, Tampa, FL.
- Department of Internal Medicine, Mount Sinai Hospital, Chicago, IL.
- Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN.
- Department of Internal Medicine, Rochester General Hospital, Rochester, NY.
- College of Public Health, University of South Florida, Tampa, FL.
Zitieren
APA
Joshi, U., Budhathoki, P., Gaire, S., Yadav, S. K., Niu, C., Agrawal, V., Low, S. K., & Soliman, H. H. (2025). Clinical Outcomes and Prognostic Factors in Epithelial-Myoepithelial Carcinoma (EMC) of the Breast. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.01.012
Vancouver
Joshi U, Budhathoki P, Gaire S, Yadav SK, Niu C, Agrawal V, et al. Clinical Outcomes and Prognostic Factors in Epithelial-Myoepithelial Carcinoma (EMC) of the Breast. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.01.012
BibTeX
@article{Joshi2025,
author = {Joshi, Utsav and Budhathoki, Pravash and Gaire, Suman and Yadav, Sumeet Kumar and Niu, Chengu and Agrawal, Vishakha and Low, Soon Khai and Soliman, Hatem Hussein},
title = {Clinical Outcomes and Prognostic Factors in Epithelial-Myoepithelial Carcinoma (EMC) of the Breast},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2025.01.012}
}
EUVIMED